What is OS Therapies's warrants and rights outstanding?

OS Therapies (OSTX) reported warrants and rights outstanding of $1.18M in Q1 2025.

What does warrants and rights outstanding mean?

This represents the total number of financial instruments that grant holders the right to purchase company equity at a specified price within a defined timeframe. It is a critical indicator of potential future dilution for existing shareholders and reflects the company's historical capital-raising activities.

OS Therapies OSTX Warrants And Rights Outstanding

Warrants And Rights Outstanding at other companies

CTO

Citius Oncology, Inc.CTOR

$6.13M—

ImmunityBio, Inc.IBRX

$308.19M+3,316%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+66.4%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:WarrantsAndRightsOutstanding.

The official record: OS Therapies’s 10-Q, filed August 18, 2025, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's warrants and rights outstanding?: OS Therapies (OSTX) reported warrants and rights outstanding of $1.18M in Q1 2025.
What does warrants and rights outstanding mean?: This represents the total number of financial instruments that grant holders the right to purchase company equity at a specified price within a defined timeframe. It is a critical indicator of potential future dilution for existing shareholders and reflects the company's historical capital-raising activities.